Recent progress on the biology of LLT1 and CD161, together with cancer signatures obtained from gene and protein expression profiling, reinforce the hypothesis that these two receptors are important players that shape antitumor immune responses and influence tumor development and progression. This evidence concerns the gene CLEC2D and neoplasm.